Clinical Trials Logo

Relapsed Small Cell Lung Cancer clinical trials

View clinical trials related to Relapsed Small Cell Lung Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06128837 Recruiting - Clinical trials for Relapsed Small Cell Lung Cancer

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Start date: March 3, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter,randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)

NCT ID: NCT05153239 Recruiting - Clinical trials for Relapsed Small Cell Lung Cancer

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Start date: July 22, 2022
Phase: Phase 3
Study type: Interventional

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

NCT ID: NCT04757779 Recruiting - Anlotinib Clinical Trials

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

Anlotinib hydrochloride is a multi-target antiangiogenic drug. It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer. This study intends to assess the efficacy and safety of anlotinib hydrochloride combined with irinotecan or docetaxel for second line treatment of nonsensitive relapsed small-cell lung cancer.

NCT ID: NCT04610658 Terminated - Clinical trials for Small-cell Lung Cancer

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Start date: November 23, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy

NCT ID: NCT04543916 Withdrawn - Clinical trials for Relapsed Small Cell Lung Cancer

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Start date: June 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, multicenter phase 1/2 trial designed to establish the recommended phase 2 dose (RP2D) of daily oral venetoclax when given in combination with irinotecan in patients with relapsed or refractory small cell lung cancer (SCLC).

NCT ID: NCT04421352 Completed - Clinical trials for Relapsed Small Cell Lung Cancer

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients

NCT ID: NCT03406715 Terminated - Lung Cancer Clinical Trials

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells. This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.